Logo image of COEP

COEPTIS THERAPEUTICS HOLDING (COEP) Stock Fundamental Analysis

USA - NASDAQ:COEP - US19207A2078 - Common Stock

12.55 USD
-0.05 (-0.4%)
Last: 9/18/2025, 8:00:00 PM
Fundamental Rating

2

COEP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 540 industry peers in the Biotechnology industry. Both the profitability and financial health of COEP have multiple concerns. COEP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

COEP had negative earnings in the past year.
COEP had a negative operating cash flow in the past year.
COEP had negative earnings in each of the past 5 years.
In the past 5 years COEP always reported negative operating cash flow.
COEP Yearly Net Income VS EBIT VS OCF VS FCFCOEP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

COEP has a Return On Assets of -260.16%. This is amonst the worse of the industry: COEP underperforms 92.78% of its industry peers.
With a Return On Equity value of -486.73%, COEP is not doing good in the industry: 77.04% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -260.16%
ROE -486.73%
ROIC N/A
ROA(3y)-312.32%
ROA(5y)N/A
ROE(3y)-615.8%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COEP Yearly ROA, ROE, ROICCOEP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K -100K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for COEP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COEP Yearly Profit, Operating, Gross MarginsCOEP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for COEP has been increased compared to 1 year ago.
Compared to 5 years ago, COEP has less shares outstanding
Compared to 1 year ago, COEP has an improved debt to assets ratio.
COEP Yearly Shares OutstandingCOEP Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
COEP Yearly Total Debt VS Total AssetsCOEP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

2.2 Solvency

COEP has an Altman-Z score of -13.83. This is a bad value and indicates that COEP is not financially healthy and even has some risk of bankruptcy.
COEP has a Altman-Z score of -13.83. This is in the lower half of the industry: COEP underperforms 78.70% of its industry peers.
COEP has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
COEP has a Debt to Equity ratio (0.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -13.83
ROIC/WACCN/A
WACCN/A
COEP Yearly LT Debt VS Equity VS FCFCOEP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M -6M

2.3 Liquidity

A Current Ratio of 1.76 indicates that COEP should not have too much problems paying its short term obligations.
The Current ratio of COEP (1.76) is worse than 78.33% of its industry peers.
A Quick Ratio of 1.76 indicates that COEP should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.76, COEP is doing worse than 77.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.76
Quick Ratio 1.76
COEP Yearly Current Assets VS Current LiabilitesCOEP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.79% over the past year.
EPS 1Y (TTM)63.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.76% on average over the next years. This is quite good.
COEP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.70% yearly.
EPS Next Y98.47%
EPS Next 2Y41.07%
EPS Next 3Y25.78%
EPS Next 5Y18.76%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y19.7%

3.3 Evolution

COEP Yearly Revenue VS EstimatesCOEP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2027 2028 2029 2030 10M 20M 30M 40M 50M
COEP Yearly EPS VS EstimatesCOEP Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

COEP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COEP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COEP Price Earnings VS Forward Price EarningsCOEP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COEP Per share dataCOEP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as COEP's earnings are expected to grow with 25.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.07%
EPS Next 3Y25.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for COEP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COEPTIS THERAPEUTICS HOLDING

NASDAQ:COEP (9/18/2025, 8:00:00 PM)

12.55

-0.05 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners4.33%
Inst Owner Change-10.96%
Ins Owners16.94%
Ins Owner Change0%
Market Cap60.49M
Analysts43.33
Price TargetN/A
Short Float %1.53%
Short Ratio1.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1072.39%
Min EPS beat(2)-2154.9%
Max EPS beat(2)10.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 14.02
P/tB 14.02
EV/EBITDA N/A
EPS(TTM)-17.58
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS0
BVpS0.9
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -260.16%
ROE -486.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-312.32%
ROA(5y)N/A
ROE(3y)-615.8%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.76
Quick Ratio 1.76
Altman-Z -13.83
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.75%
EPS Next Y98.47%
EPS Next 2Y41.07%
EPS Next 3Y25.78%
EPS Next 5Y18.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y19.7%
EBIT growth 1Y64.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year132.72%
EBIT Next 3Y-3%
EBIT Next 5Y14.87%
FCF growth 1Y-86.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.79%
OCF growth 3YN/A
OCF growth 5YN/A